278 related articles for article (PubMed ID: 21779447)
1. DNA demethylating antineoplastic strategies: a comparative point of view.
Amatori S; Bagaloni I; Donati B; Fanelli M
Genes Cancer; 2010 Mar; 1(3):197-209. PubMed ID: 21779447
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation as a target of epigenetic therapeutics in cancer.
Li KK; Li F; Li QS; Yang K; Jin B
Anticancer Agents Med Chem; 2013 Feb; 13(2):242-7. PubMed ID: 22934696
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
4. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.
Murgo AJ
Semin Oncol; 2005 Oct; 32(5):458-64. PubMed ID: 16210086
[TBL] [Abstract][Full Text] [Related]
5. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
6. DNA demethylating agents and epigenetic therapy of cancer.
Mani S; Herceg Z
Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
[TBL] [Abstract][Full Text] [Related]
7. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation and cancer.
Das PM; Singal R
J Clin Oncol; 2004 Nov; 22(22):4632-42. PubMed ID: 15542813
[TBL] [Abstract][Full Text] [Related]
9. Advances in Epigenetic Cancer Therapeutics.
Hillyar C; Rallis KS; Varghese J
Cureus; 2020 Nov; 12(11):e11725. PubMed ID: 33391954
[TBL] [Abstract][Full Text] [Related]
10. Epigenetics in cancer: targeting chromatin modifications.
Ellis L; Atadja PW; Johnstone RW
Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
[TBL] [Abstract][Full Text] [Related]
11. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
12. Insights into novel emerging epigenetic drugs in myeloid malignancies.
Chandhok NS; Prebet T
Ther Adv Hematol; 2019; 10():2040620719866081. PubMed ID: 31431820
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries.
Wongtrakoongate P
World J Stem Cells; 2015 Jan; 7(1):137-48. PubMed ID: 25621113
[TBL] [Abstract][Full Text] [Related]
14. Environmental toxicants, incidence of degenerative diseases, and therapies from the epigenetic point of view.
Hodjat M; Rahmani S; Khan F; Niaz K; Navaei-Nigjeh M; Mohammadi Nejad S; Abdollahi M
Arch Toxicol; 2017 Jul; 91(7):2577-2597. PubMed ID: 28516248
[TBL] [Abstract][Full Text] [Related]
15. Deregulation of epigenetic mechanisms in cancer.
Maleszewska M; Wojtas B; Kamińska B
Postepy Biochem; 2018 Oct; 64(2):148-156. PubMed ID: 30656897
[TBL] [Abstract][Full Text] [Related]
16. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
Saleh R; Toor SM; Sasidharan Nair V; Elkord E
Front Immunol; 2020; 11():1469. PubMed ID: 32760400
[TBL] [Abstract][Full Text] [Related]
17. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic targets in hematopoietic malignancies.
Claus R; Lübbert M
Oncogene; 2003 Sep; 22(42):6489-96. PubMed ID: 14528273
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy.
Maio M; Covre A; Fratta E; Di Giacomo AM; Taverna P; Natali PG; Coral S; Sigalotti L
Clin Cancer Res; 2015 Sep; 21(18):4040-7. PubMed ID: 26374074
[TBL] [Abstract][Full Text] [Related]
20. Interpreting clinical assays for histone deacetylase inhibitors.
Martinet N; Bertrand P
Cancer Manag Res; 2011; 3():117-41. PubMed ID: 21625397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
